NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky is investigating potential claims on behalf of purchasers of Atossa Genetics, Inc. (“Atossa” or the “Company”) (Nasdaq:ATOS) securities concerning possible violations of securities laws.
For more information, click here: http://zlk.9nl.com/atossa-genetics-atos.
On October 4, 2013, Atossa announced a voluntary recall (the “recall”) of its ForeCYTE Breast Health Test Mammary Aspiration Specimen Cytology Test (MASCT), including the recall of the MASCT System Kit and Patient Sample Kit. The recall commenced to address concerns raised in a February 2013 warning letter issued by the U.S. Food and Drug Administration (the “FDA”), in which the FDA raised concerns regarding the current instructions for use (IFU), certain promotional claims used to market these devices, and regarding the need for FDA clearance for certain changes made to the Nipple Aspirate Fluid (NAF) specimen collection process identified in the current IFU.
If you own Atossa stock and wish to obtain additional information about the investigation and your legal rights, please contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/atossa-genetics-atos.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.